Evidence map›Paper›PMID 37466878›Full record

ArticleInsights into imaging2023

Automatic analysis framework based on 3D-CT multi-scale features for accurate prediction of Ki67 expression levels in substantial renal cell carcinoma.

Huancheng Yang, Jiashan Lin, Hanlin Liu, Jiehua Yao, Qianyu Lin, Jiaxin Wang, Feiye Jiang, Liying Wei, Chongyang Lin, Kai Wu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Insights into imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Huancheng Yang *Luohu Clinical Institute, Shantou University Medical College, Shantou, 515000, China.
Jiashan Lin *Luohu Clinical Institute, Shantou University Medical College, Shantou, 515000, China.
Hanlin Liu *Department of Radiology, The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group), Shenzhen, 518000, China.
Jiehua YaoShantou University Medical College, Shantou University, Shantou, 515000, China.
Qianyu LinShantou University Medical College, Shantou University, Shantou, 515000, China.
Jiaxin WangShantou University Medical College, Shantou University, Shantou, 515000, China.
Feiye JiangShantou University Medical College, Shantou University, Shantou, 515000, China.
Liying WeiShantou University Medical College, Shantou University, Shantou, 515000, China.
Chongyang LinShantou University Medical College, Shantou University, Shantou, 515000, China.
Kai WuShenzhen Following Precision Medical Research Institute, Luohu Hospital Group, Shenzhen, 51800, China. wukai1990@hotmail.com.
Song WuLuohu Clinical Institute, Shantou University Medical College, Shantou, 515000, China. wusong@szu.edu.cn.
Shantou University Medical College · CNShantou University · CNShenzhen Luohu People's Hospital · CNPeking University Shenzhen Hospital · CNShenzhen University Health Science Center · CN

Funding

National Natural Science Foundation Fund of China No. 61931024Shenzhen Municipal Science and Technology Innovation Commission No. JSGG20180712090411521Shenzhen Science and Technology Innovation Program No. JCYJ20220818100015031Shenzhen Science and Technology Innovation Program No. RCJC20200714114557005
6 · The paper itself

Abstract

purposeTo investigate the effectiveness of an automatic analysis framework based on 3D-CT multi-scale features in predicting Ki67 expression levels in substantial renal cell carcinoma (RCC).

methodsThis retrospective study was conducted using multi-center cohorts consisting of 588 participants with pathologically confirmed RCC. The participants were divided into an internal training set (n = 485) and an external testing set (n = 103) from four and one local hospitals, respectively. The proposed automatic analytic framework comprised a 3D kidney and tumor segmentation model constructed by 3D UNet, a 3D-CT multi-scale features extractor based on the renal-tumor feature, and a low or high Ki67 prediction classifier using XGBoost. The framework was validated using a fivefold cross-validation strategy. The Shapley additive explanation (SHAP) method was used to determine the contribution of each feature.

resultsIn the prediction of low or high Ki67, the combination of renal and tumor features achieved better performance than any single features. Internal validation using a fivefold cross-validation strategy yielded AUROC values of 0.75 ± 0.1, 0.75 ± 0.1, 0.83 ± 0.1, 0.77 ± 0.1, and 0.87 ± 0.1, respectively. The optimal model achieved an AUROC of 0.87 ± 0.1 and 0.82 ± 0.1 for low vs. high Ki67 prediction in the internal validation and external testing sets, respectively. Notably, the tumor first-order-10P was identified as the most influential feature in the model decision.

conclusionsOur study suggests that the proposed automatic analysis framework based on 3D-CT multi-scale features has great potential for accurately predicting Ki67 expression levels in substantial RCC. CRITICAL RELEVANCE STATEMENT: Automatic analysis framework based on 3D-CT multi-scale features provides reliable predictions for Ki67 expression levels in substantial RCC, indicating the potential usage of clinical applications.

Indexed as

Ki67Multi-scale featuresRenal cell carcinoma

Identifiers

PMID37466878
PMCPMC10356689
OpenAlexW4384664968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.